US7767449B1
(en)
|
1981-12-24 |
2010-08-03 |
Health Research Incorporated |
Methods using modified vaccinia virus
|
US5174993A
(en)
*
|
1981-12-24 |
1992-12-29 |
Health Research Inc. |
Recombinant avipox virus and immunological use thereof
|
US5833975A
(en)
*
|
1989-03-08 |
1998-11-10 |
Virogenetics Corporation |
Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
|
CA1340203C
(en)
*
|
1987-09-16 |
1998-12-15 |
Noboru Yanagida |
Recombinant apivoxvirus
|
WO1990010693A1
(en)
*
|
1989-03-08 |
1990-09-20 |
Health Research, Inc. |
Recombinant poxvirus host selection system
|
US5766597A
(en)
*
|
1991-03-07 |
1998-06-16 |
Virogenetics Corporation |
Malaria recombinant poxviruses
|
US5766598A
(en)
*
|
1991-03-07 |
1998-06-16 |
Virogenetics Corporation |
Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
|
WO1992016616A1
(en)
*
|
1991-03-20 |
1992-10-01 |
Virogenetics Corporation |
Malaria recombinant poxvirus vaccine
|
WO1995011700A1
(en)
*
|
1993-10-29 |
1995-05-04 |
Pharmos Corp. |
Submicron emulsions as vaccine adjuvants
|
US5961970A
(en)
*
|
1993-10-29 |
1999-10-05 |
Pharmos Corporation |
Submicron emulsions as vaccine adjuvants
|
UA68327C2
(en)
*
|
1995-07-04 |
2004-08-16 |
Gsf Forschungszentrum Fur Unwe |
A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
|
EP0753581A1
(en)
*
|
1995-07-10 |
1997-01-15 |
Immuno Ag |
Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
|
ID19548A
(id)
*
|
1996-09-24 |
1998-07-23 |
Bavarian Nordic Res Inst As |
Virus mva rekombinan yang mengekspresikan antigen-antigen virus demam dan penggunaan daripadanya dalam vaksin-vaksin
|
GB9711957D0
(en)
|
1997-06-09 |
1997-08-06 |
Isis Innovation |
Methods and reagents for vaccination
|
US20030138454A1
(en)
*
|
1997-06-09 |
2003-07-24 |
Oxxon Pharmaccines, Ltd. |
Vaccination method
|
US6572874B1
(en)
|
1998-05-15 |
2003-06-03 |
Umd, Inc. |
Vaginal delivery of bisphosphonates
|
US6416779B1
(en)
|
1997-06-11 |
2002-07-09 |
Umd, Inc. |
Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
|
US6197327B1
(en)
*
|
1997-06-11 |
2001-03-06 |
Umd, Inc. |
Device and method for treatment of dysmenorrhea
|
FR2766091A1
(fr)
|
1997-07-18 |
1999-01-22 |
Transgene Sa |
Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
|
US6969609B1
(en)
*
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
US6582693B2
(en)
*
|
1998-11-30 |
2003-06-24 |
Lemery, S.A. De C.V. |
Recombinant MVA virus expressing the E2 gene of Bovine papillomavirus and its use in the therapy of tumors generated by papillomaviruses
|
US20040265324A1
(en)
*
|
1999-03-23 |
2004-12-30 |
Cardosa Mary Jane |
Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
|
DK1180155T3
(da)
*
|
1999-05-28 |
2009-02-16 |
Helmholtz Zentrum Muenchen |
Vektor til integration af heterologe sekvenser i poxvirale genomer
|
US6497883B1
(en)
|
1999-06-10 |
2002-12-24 |
Merial |
Porcine circovirus recombinant poxvirus vaccine
|
AU1013601A
(en)
|
1999-10-22 |
2001-05-08 |
Aventis Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
US20040105871A1
(en)
*
|
2000-03-02 |
2004-06-03 |
Robinson Harriet L. |
Compositions and methods for generating an immune response
|
WO2001092470A2
(en)
|
2000-03-02 |
2001-12-06 |
Emory University |
Dna expression vectors and methods of use
|
US8623379B2
(en)
*
|
2000-03-02 |
2014-01-07 |
Emory University |
Compositions and methods for generating an immune response
|
DK1263936T3
(da)
*
|
2000-03-14 |
2006-02-13 |
Bavarian Nordic As |
andret stamme af den modificerede Vacciniavirus Ankara (MVA)
|
DK1282702T3
(da)
*
|
2000-05-10 |
2007-04-02 |
Sanofi Pasteur Ltd |
Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
|
DE10042598A1
(de)
*
|
2000-08-30 |
2002-03-28 |
Gsf Forschungszentrum Umwelt |
Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
|
US7445924B2
(en)
*
|
2000-11-23 |
2008-11-04 |
Bavarian Nordic A/S |
Modified Vaccinia Ankara virus variant and cultivation method
|
CN100537773C
(zh)
|
2000-11-23 |
2009-09-09 |
巴法里安诺迪克有限公司 |
改良安卡拉痘苗病毒变体
|
CN1176945C
(zh)
*
|
2001-02-01 |
2004-11-24 |
中国人民解放军第二军医大学 |
疟原虫融合抗原及其制法和用途
|
AU2002252199B2
(en)
*
|
2001-03-08 |
2008-01-03 |
Emory University |
MVA expressing modified HIV envelope, GAG, and POL genes
|
UA82466C2
(uk)
*
|
2001-07-18 |
2008-04-25 |
Бавариан Нордика А/С |
Спосіб посилення ампліфікації хордопоксвірусу
|
GB0118532D0
(en)
*
|
2001-07-30 |
2001-09-19 |
Isis Innovation |
Materials and methods relating to improved vaccination strategies
|
DE10144664B4
(de)
*
|
2001-09-11 |
2005-06-09 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
|
CN1880457B
(zh)
|
2001-10-11 |
2010-05-26 |
麦克公司 |
Ad6重组核酸
|
EP1450854A2
(en)
|
2001-11-30 |
2004-09-01 |
Isis Innovation Limited |
Vaccine
|
BR0214822A
(pt)
*
|
2001-12-10 |
2004-12-14 |
Bavarian Nordic As |
Formulações contendo poxvìrus e processo para preparar composições contendo poxvìrus estáveis
|
AU2002364161A1
(en)
*
|
2001-12-12 |
2003-06-23 |
Aventis Pasteur Limited |
Enhancement of the immune response using cd36-binding domain
|
US7501127B2
(en)
|
2002-05-16 |
2009-03-10 |
Bavarian Nordic A/S |
Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
|
ATE393212T2
(de)
*
|
2002-09-05 |
2008-05-15 |
Bavarian Nordic As |
Verfahren zur amplifikation von einem poxvirus in serumfreien verhältnissen
|
WO2004058801A2
(en)
*
|
2002-12-23 |
2004-07-15 |
City Of Hope |
Modified vaccinia ankara expressing p53 in cancer immunotherapy
|
JP5052893B2
(ja)
*
|
2003-02-20 |
2012-10-17 |
アメリカ合衆国 |
ポックスベクターにおける新規の挿入部位
|
US20050175627A1
(en)
*
|
2003-09-24 |
2005-08-11 |
Oxxon Therapeutics Ltd. |
HIV pharmaccines
|
US7998733B2
(en)
|
2004-10-05 |
2011-08-16 |
Merial Limited |
Chimeric vectors
|
JP5475279B2
(ja)
|
2005-06-17 |
2014-04-16 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ |
C型肝炎ウイルス核酸ワクチン
|
US20090060947A1
(en)
*
|
2006-05-19 |
2009-03-05 |
Sanofi Pasteur, Inc. |
Immunological compositions
|
US20080010527A1
(en)
*
|
2006-06-26 |
2008-01-10 |
Inventec Corporation |
Method of solving BIST failure of CPU by means of BIOS and maximizing system performance
|
EP2064351A1
(en)
*
|
2006-09-08 |
2009-06-03 |
Bavarian Nordic A/S |
Phenotypic and genotypic differences of mva strains
|
NZ575388A
(en)
|
2006-10-06 |
2012-03-30 |
Bn Immunotherapeutics Inc |
Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer
|
BRPI0908474A2
(pt)
|
2008-02-12 |
2016-07-26 |
Sanofi Pasteur Ltd |
métodos de uso de cromatografia de troca de íon e de filtração de gel para purificação de vírus causador da catapora
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
US7998488B2
(en)
*
|
2008-11-14 |
2011-08-16 |
Baxter International Inc. |
Vaccine formulations and uses thereof
|
US9670506B2
(en)
|
2009-04-30 |
2017-06-06 |
Consejo Superior De Investigaciones Cientificas |
Modified immunization vectors
|
WO2011087839A1
(en)
|
2009-12-22 |
2011-07-21 |
Baxter International Inc. |
Vaccine to influenza a virus
|
JP5783642B2
(ja)
|
2010-01-28 |
2015-09-24 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
Mvaの主なゲノム欠失を含むワクシニアウイルス変異体
|
EP2944322B1
(en)
|
2010-03-12 |
2018-01-17 |
Merial, Inc |
Bluetongue virus recombinant vaccines and uses thereof
|
WO2012101509A2
(en)
|
2011-01-28 |
2012-08-02 |
Sanofi Pasteur Sa |
Immunological compositions against hiv
|
WO2012151272A2
(en)
|
2011-05-02 |
2012-11-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
EP2788021B1
(en)
|
2011-12-09 |
2017-01-18 |
Bavarian Nordic A/S |
Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
|
EA201891945A3
(ru)
|
2012-08-01 |
2019-05-31 |
Бавариан Нордик А/С |
Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
|
EP3639851A1
(en)
|
2012-09-04 |
2020-04-22 |
Bavarian Nordic A/S |
Methods and compositions for enhancing vaccine immune responses
|
EP2908851A1
(en)
|
2012-10-19 |
2015-08-26 |
Bavarian Nordic Inc. |
Methods and compositions for the treatment of cancer
|
WO2014140938A2
(en)
|
2013-03-14 |
2014-09-18 |
Centre Hospitalier Universitaire Vaudois |
Immunological methods
|
DE102013004595A1
(de)
|
2013-03-15 |
2014-09-18 |
Emergent Product Development Germany Gmbh |
RSV-Impfstoffe
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
JP6641276B2
(ja)
|
2013-11-28 |
2020-02-05 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
CN106456724A
(zh)
|
2013-12-20 |
2017-02-22 |
博德研究所 |
使用新抗原疫苗的联合疗法
|
JP2017515841A
(ja)
|
2014-05-13 |
2017-06-15 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
腫瘍抗原を発現するポックスウイルス及びtim−3に対するモノクローナル抗体を用いた癌治療のための併用療法
|
PT3188753T
(pt)
|
2014-09-03 |
2020-03-25 |
Bavarian Nordic As |
Métodos e composições para induzir imunidade protetora contra infeção por filovírus
|
AP2017009822A0
(en)
|
2014-09-03 |
2017-03-31 |
Bavarian Nordic As |
Methods and compositions for enhancing immune responses
|
EP3197489B1
(en)
|
2014-09-26 |
2021-02-17 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
|
EP3234130B1
(en)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Methods for profiling the t-cell- receptor repertoire
|
EP3234193B1
(en)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molecular biomarkers for cancer immunotherapy
|
AU2016232050B2
(en)
|
2015-03-18 |
2022-04-07 |
Janssen Vaccines & Prevention B.V. |
Assays for recombinant expression systems
|
TWI806815B
(zh)
|
2015-05-20 |
2023-07-01 |
美商博德研究所有限公司 |
共有之gata3相關之腫瘤特異性新抗原
|
LT3390430T
(lt)
|
2015-12-15 |
2019-11-25 |
Janssen Vaccines & Prevention Bv |
Žmogaus imunodeficito antigenai, vektoriai, kompozicijos ir jų panaudojimo būdai
|
PL3407910T3
(pl)
|
2016-01-29 |
2022-08-16 |
Bavarian Nordic A/S |
Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
EA201892735A1
(ru)
|
2016-06-16 |
2019-05-31 |
Янссен Вэксинс Энд Превеншн Б.В. |
Состав вакцины против hiv
|
US10925956B2
(en)
|
2016-07-15 |
2021-02-23 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against a marburg virus infection
|
CN110494159A
(zh)
|
2016-09-02 |
2019-11-22 |
扬森疫苗与预防公司 |
在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法
|
EP3512543B1
(en)
|
2016-09-15 |
2020-07-22 |
Janssen Vaccines & Prevention B.V. |
Trimer stabilizing hiv envelope protein mutations
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
SI3580561T1
(sl)
|
2017-02-12 |
2024-04-30 |
Biontech Us Inc. |
Metode, osnovane na hla, in njihove sestave ter uporabe
|
EP3606553A1
(en)
|
2017-04-06 |
2020-02-12 |
Janssen Vaccines & Prevention B.V. |
Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
|
BR112019026126A2
(pt)
|
2017-06-15 |
2020-06-30 |
Janssen Vaccines & Prevention B.V. |
vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
|
MA49616A
(fr)
|
2017-07-19 |
2020-05-27 |
Janssen Vaccines & Prevention Bv |
Mutations de protéine d'enveloppe du vih stabilisant la forme trimère
|
US20190022212A1
(en)
|
2017-07-21 |
2019-01-24 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
|
US20190083620A1
(en)
|
2017-09-18 |
2019-03-21 |
Janssen Vaccines & Prevention B.V. |
Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
|
TW201930340A
(zh)
|
2017-12-18 |
2019-08-01 |
美商尼恩醫療公司 |
新抗原及其用途
|
EP3851120A4
(en)
|
2018-09-11 |
2022-04-27 |
Shanghai Public Health Clinical Center |
IMMUNOGEN FOR BROAD-SPECTRUM INFLUENZA VACCINE, AND APPLICATION THEREOF
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
CN113474840A
(zh)
|
2018-12-21 |
2021-10-01 |
百欧恩泰美国公司 |
用于预测hla ii类特异性表位及表征cd4+ t细胞的方法和***
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
***新抗原及其用途
|
IL293051A
(en)
|
2019-11-18 |
2022-07-01 |
Janssen Biotech Inc |
calr and jak2 mutant-based vaccines and their uses
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
WO2021209897A1
(en)
|
2020-04-13 |
2021-10-21 |
Janssen Biotech, Inc. |
Psma and steap1 vaccines and their uses
|
US20230203477A1
(en)
|
2020-05-26 |
2023-06-29 |
The Broad Institute, Inc. |
Nucleic acid artificial mini-proteome libraries
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
US20230035403A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Method For Determining Responsiveness To Prostate Cancer Treatment
|
EP4175721A1
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
JP2024501482A
(ja)
|
2020-12-14 |
2024-01-12 |
ビオンテック ユーエス インコーポレイテッド |
がん免疫療法のための組織特異的抗原
|
WO2023076733A1
(en)
|
2021-11-01 |
2023-05-04 |
Dana-Farber Cancer Institute, Inc. |
Biologically selected nucleic acid artificial mini-proteome libraries
|
WO2023077147A2
(en)
|
2021-11-01 |
2023-05-04 |
Pellis Therapeutics, Inc. |
T-cell vaccines for patients with reduced humoral immunity
|
WO2023198815A1
(en)
|
2022-04-14 |
2023-10-19 |
Janssen Vaccines & Prevention B.V. |
Sequential administration of adenoviruses
|
WO2023220283A1
(en)
|
2022-05-12 |
2023-11-16 |
Pellis Therapeutics, Inc. |
Poxvirus adjuvant for t-cell vaccination
|
US20240033347A1
(en)
|
2022-07-08 |
2024-02-01 |
Viromissile, Inc. |
Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof
|
WO2024015892A1
(en)
|
2022-07-13 |
2024-01-18 |
The Broad Institute, Inc. |
Hla-ii immunopeptidome methods and systems for antigen discovery
|